17 results on '"Gold, Ronit"'
Search Results
2. Polatuzumab-based regimen or CAR T cell for patients with refractory/relapsed DLBCL—a matched cohort analysis
3. [18F]FDG PET-CT in patients with DLBCL treated with CAR-T cell therapy: a practical approach of reporting pre- and post-treatment studies
4. Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients after Allogeneic HCT or CD19-based CART therapy—A Single-Center Prospective Cohort Study
5. Response rates of extra‐nodal diffuse large B cell lymphoma to anti‐CD19‐CAR T cells: A real word retrospective multicenter study
6. Response Rates of Extra-Nodal Diffuse Large B Cell Lymphoma to anti CD19-CAR T Cells - a Real Word Retrospective Multi-Center Study
7. Response Rates of Extra-Nodal Diffuse Large B Cell Lymphoma to CD19-CAR T Cells - a Real Word Retrospective Multi-Center Study
8. Immunogenicity of a Third Dose of the BNT162b2 mRNA Covid-19 Vaccine in Patients with Impaired B Cell Reconstitution After Cellular Therapy—A Single Center Prospective Cohort Study
9. A Comprehensive Toxicity and Efficacy Analysis of Different Bridging Therapies Prior to Anti CD19-CAR-T Cell Therapy in Patients with DLBCL- a National Multi-Center Cohort Study
10. Characteristics and recognition of early infections in patients treated with commercial anti‐CD19 CAR‐T cells
11. [18F]FDG PET-CT in patients with DLBCL treated with CAR-T cell therapy: a practical approach of reporting pre- and post-treatment studies
12. Toxicity and efficacy of chimeric antigen receptor T-cell therapy in patients with diffuse large B-cell lymphoma above the age of 70 years compared to younger patients – a matched control multicenter cohort study
13. Toxicity and Efficacy of CAR-T in Patients with DLBCL Above the Age of 70 Years Compare to Younger Patients – a Matched Control Multi-Center Cohort Study
14. [18F]FDG PET-CT in patients with DLBCL treated with CAR-T cell therapy: a practical approach of reporting pre- and post-treatment studies.
15. Characteristics and recognition of early infections in patients treated with commercial anti‐CD19 CAR‐T cells.
16. 51 - Toxicity and Efficacy of CAR-T in Patients with DLBCL Above the Age of 70 Years Compare to Younger Patients – a Matched Control Multi-Center Cohort Study
17. Toxicity and efficacy of chimeric antigen receptor T-cell therapy in patients with diffuse large B-cell lymphoma above the age of 70 years compared to younger patients - a matched control multicenter cohort study.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.